Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


  •  Dr Sarah Gooding (MRC MHU, MRC WIMM, NDCLS) CRUK Clinician Scientist Fellowship. Title: Exploiting recurrent chromosome copy number alteration (CNA)-driven defects in the treatment of Multiple Myeloma
  • Professor Ross Chapman (MRC MHU, MRC WIMM, NDCLS) CRUK Senior Research Fellowship. Title: Mechanisms underpinning distinct manifestations of Homologous Recombination deficiency in cancer
  • Dr Ewa Gogola (MRC MHU, MRC WIMM, NDCLS) Wellcome Early-Career Award. Title: DNA damage-induced hepatocyte polyploidisation – how it happens and what are its consequences?
  • Dr Bing Tseu (MRC MHU, MRC WIMM, NDCLS) MRC Clinical Research Training Fellowship. Title: Graft versus Leukaemia (GvL): Identification & characterisation of GVL antigens and cognate T cell responses in Acute Myeloid Leukaemia
  • Dr Naveed Akbar (CVM) BHF Intermediate Basic Science Research Fellowship Title: Harnessing endothelial cell extracellular vesicles in acute myocardial infarction
  • Associate Professor Svetlana Reilly (CVM) BHF Senior Basic Science Research Fellowship Title: Molecular mechanisms of aberrant calcitonin receptor localisation in human atrial fibroblasts in persistent atrial fibrillation
  • Associate Professor Oliver Rider (CVM) BHF Senior Clinical Research Fellowship to investigate the relationship between cardiac substrate metabolism, cardiac energetics and cardiac function in multiple diseases with a focus on cardiometabolic heart disease and heart failure
  • Dr Nicolas Crump (MRC MHU, MRC WIMM, NDCLS) KKLF Intermediate Research Fellowship Title: Probing the role of novel enhancer usage in acquired drug resistance